Viral contamination in biologic manufacture and implications for emerging therapies

[1]  M. Eloit,et al.  Use of a new RNA next generation sequencing approach for the specific detection of virus infection in cells. , 2019, Biologicals : journal of the International Association of Biological Standardization.

[2]  Michael DiCuccio,et al.  Erratum: The long view on sequencing , 2018, Nature Biotechnology.

[3]  FDA approves hereditary blindness gene therapy , 2018, Nature Biotechnology.

[4]  E. Waltz.  With a free pass, CRISPR-edited plants reach market in record time , 2018, Nature Biotechnology.

[5]  Asher Mullard,et al.  Second anticancer CAR T therapy receives FDA approval , 2017, Nature Reviews Drug Discovery.

[6]  Asher Mullard,et al.  BTK inhibitors get a boost , 2017, Nature Reviews Drug Discovery.

[7]  R. L. Charlebois,et al.  A Multicenter Study To Evaluate the Performance of High-Throughput Sequencing for Virus Detection , 2017, mSphere.

[8]  Shakir Ali,et al.  Microbial and viral contamination of animal and stem cell cultures: common contaminants, detection and elimination , 2017 .

[9]  M. Aucoin,et al.  Evaluating ultraviolet sensitivity of adventitious agents in biopharmaceutical manufacturing , 2017, Journal of Industrial Microbiology & Biotechnology.

[10]  Arifa S Khan,et al.  Advanced Virus Detection Technologies Interest Group (AVDTIG): Efforts on High Throughput Sequencing (HTS) for Virus Detection , 2016, PDA Journal of Pharmaceutical Science and Technology.

[11]  K. Bergmann,et al.  Vesivirus 2117: Cell line infectivity range and effectiveness of amplification of a potential adventitious agent in cell culture used for biological production. , 2016, Biologicals : journal of the International Association of Biological Standardization.

[12]  Sarfaraz K Niazi.  Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin , 2016, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition.

[13]  M. Takagi,et al.  Design of serum-free medium for suspension culture of CHO cells on the basis of general commercial media , 2015, Cytotechnology.

[14]  Hazel Aranha,et al.  Viral clearance for biopharmaceutical downstream processes , 2015 .

[15]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2014 , 2014, Nature Biotechnology.

[16]  G. Ye,et al.  Herpes simplex virus clearance during purification of a recombinant adeno-associated virus serotype 1 vector. , 2014, Human gene therapy. Clinical development.

[17]  P. Duncan,et al.  Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products. , 2014, Vaccine.

[18]  K. Brorson,et al.  Meeting Report: 2013 PDA Virus & TSE Safety Forum , 2014, PDA Journal of Pharmaceutical Science and Technology.

[19]  T. Wirth,et al.  History of gene therapy. , 2013, Gene.

[20]  Kate Zhang,et al.  Identification and quantitation of vesivirus 2117 particles in bioreactor fluids from infected Chinese hamster ovary cell cultures , 2013, Biotechnology and bioengineering.

[21]  Dayue Chen,et al.  Effectiveness of mouse minute virus inactivation by high temperature short time treatment technology: a statistical assessment. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[22]  F. Khan,et al.  Mouse Minute Virus (MMV) Contamination—A Case Study: Detection, Root Cause Determination, and Corrective Actions , 2011, PDA Journal of Pharmaceutical Science and Technology.

[23]  R. Kiss.  Practicing Safe Cell Culture: Applied Process Designs for Minimizing Virus Contamination Risk , 2011, PDA Journal of Pharmaceutical Science and Technology.

[24]  P. Krause,et al.  Molecular and infectivity studies of porcine circovirus in vaccines. , 2011, Vaccine.

[25]  Y. Qiu,et al.  Caliciviridae and Vesivirus 2117 , 2011 .

[26]  N. Bannert,et al.  Analysis of porcine circovirus type 1 detected in Rotarix vaccine. , 2011, Vaccine.

[27]  R. Nims,et al.  Gamma-irradiation of serum for the inactivation of adventitious contaminants. , 2010, PDA journal of pharmaceutical science and technology.

[28]  Mike Rubino.  Experiences with HEK293: A Human Cell Line. , 2010, PDA journal of pharmaceutical science and technology.

[29]  Crystal Jaing,et al.  Viral Nucleic Acids in Live-Attenuated Vaccines: Detection of Minority Variants and an Adventitious Virus , 2010, Journal of Virology.

[30]  Malorye Allison.  As Genzyme flounders, competitors and activist investors swoop in , 2010, Nature Biotechnology.

[31]  Victor Bethencourt.  Virus stalls Genzyme plant , 2009, Nature Biotechnology.

[32]  Prince Bhebe,et al.  Susceptibility of mouse minute virus to inactivation by heat in two cell culture media types , 2009, Biotechnology progress.

[33]  Thomas R Kreil,et al.  Emerging trends in plasma‐free manufacturing of recombinant protein therapeutics expressed in mammalian cells , 2009, Biotechnology journal.

[34]  T. Burnouf.  Modern Plasma Fractionation , 2007, Transfusion Medicine Reviews.

[35]  Steven Kozlowski,et al.  Current and future issues in the manufacturing and development of monoclonal antibodies. , 2006, Advanced drug delivery reviews.

[36]  J. P. Davis,et al.  Second Human Case of Cache Valley Virus Disease , 2006, Emerging infectious diseases.

[37]  Kurt Brorson,et al.  The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. , 2005, Current opinion in biotechnology.

[38]  M. Büttner,et al.  Identification of a calicivirus isolate of unknown origin. , 2003, The Journal of general virology.

[39]  O. Merten.  Virus contaminations of cell cultures – A biotechnological view , 2002, Cytotechnology.

[40]  C. Bennett,et al.  Legal, Financial, and Public Health Consequences of HIV Contamination of Blood and Blood Products in the 1980s and 1990s , 2002, Annals of Internal Medicine.

[41]  A. Ault.  US FDA again stops urokinase sales , 1999, The Lancet.

[42]  D. Sexton,et al.  Life-threatening Cache Valley virus infection. , 1997, The New England journal of medicine.

[43]  Louise Poissant.  Part I , 1996, Leonardo.

[44]  D. Besselsen,et al.  Molecular characterization of newly recognized rodent parvoviruses. , 1996, The Journal of general virology.

[45]  D. Swinbanks,et al.  Health ministry accepts liability in Japanese HIV-infected blood row , 1996, Nature.

[46]  D. Butler.  Petition prompts backlash against scientists , 1994, Nature.

[47]  P. Mellor,et al.  Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV). , 1993, Biologicals : journal of the International Association of Biological Standardization.

[48]  F. Rosendaal,et al.  Hemophilia treatment in historical perspective: a review of medical and social developments , 1991, Annals of Hematology.

[49]  Mary K. Joscelyn,et al.  Review and comment , 1977 .

[50]  M. Eaton,et al.  JAUNDICE IN ARMY PERSONNEL IN THE WESTERN REGION OF THE UNITED STATES AND ITS RELATION TO VACCINATION AGAINST YELLOW FEVERPART I , 1944 .

[51]  T. Walter.  A UNITED FRONT , 1935 .

[52]  Achilleas Zapranis,et al.  A Statistical Assessment , 2016 .

[53]  Karen Godfrey-Edwards.  A united front. , 2013, Midwives.

[54]  Chris Mason,et al.  Peak serum: implications of serum supply for cell therapy manufacturing. , 2012, Regenerative medicine.

[55]  D. Onions,et al.  Detection of Cache Valley Virus in Biologics Manufactured in CHO Cells , 2008 .

[56]  R. Nims.  Detection of adventitious viruses in biologicals--a rare occurrence. , 2006, Developments in biologicals.

[57]  Nims Rw.  Detection of adventitious viruses in biologicals--a rare occurrence. , 2006 .

[58]  S. Lute,et al.  Current and future approaches to ensure the viral safety of biopharmaceuticals. , 2004, Developments in biologicals.

[59]  Donna A. Almario,et al.  Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer , 2003 .

[60]  Donna A. Almario,et al.  Immunization Safety Review , 2002 .

[61]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.

[62]  J. Vennari,et al.  Development and Qualification of a Novel Virus Removal Filter for Cell Culture Applications , 2000, Biotechnology progress.

[63]  F. Brown,et al.  WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (Requirements for biological substances N°50) : Safety of Biological Products Prepared from Mammalian Cell Culture , 1998 .

[64]  Garnick Rl.  Raw materials as a source of contamination in large-scale cell culture. , 1998 .

[65]  R L Garnick,et al.  Experience with viral contamination in cell culture. , 1996, Developments in biological standardization.

[66]  D. Burstyn.  Contamination of genetically engineered Chinese hamster ovary cells. , 1996, Developments in biological standardization.

[67]  H. Suomela.  Inactivation of viruses in blood and plasma products. , 1993, Transfusion medicine reviews.

[68]  N. Nathanson,et al.  Human exposure to SV40: review and comment. , 1976, American journal of epidemiology.